Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies

In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Osteoboost.Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Laura Yecies.KEY MOMENTS FROM THE INTERVIEW(02:49) - An overview of Laura’s background and her transition from consumer tech to medtech (04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need (08:31) - How Osteoboost designed its device with the consumer experience in mind (15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path (19:50) - How to design clinical trials that reflect real-world use and drive patient compliance (25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization (28:48) - Why Laura believed the problem wasn’t demand — it was lack of options (33:57) - How patients can become a powerful “sales force” in healthcare (38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later